Comparative efficacy of immune checkpoint inhibitor-based regimens versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma stratified by etiology: a systematic review and meta-analysis

Puntos clave

• Immune checkpoint inhibitors show superior efficacy compared to tyrosine kinase inhibitors in treating advanced hepatocellular carcinoma.
• The analysis involved data from several clinical studies, indicating a clear therapeutic advantage in specific patient groups.
• Systematic review and meta-analysis revealed significant differences in treatment outcomes based on etiology-related factors.
• Findings may influence future treatment recommendations, with a need for further trials to validate efficacy across diverse patient profiles.